Earnings ·
CeriBell reported second quarter 2026 financial results with total revenue of $28.1 million, a 33% increase from the…
CBLLCeribell, Inc.
CeriBell reported second quarter 2026 financial results with total revenue of $28.1 million, a 33% increase from the prior year period. The company achieved a gross margin of 92%, driven by manufacturing cost reductions and tariff refunds, while operating expenses rose to $45.9 million due to commercial expansion and intellectual property litigation costs. Net loss widened to $19.3 million, or $0.51 per share, compared to $13.6 million in the same period last year. CeriBell secured a new credit facility providing up to $60 million in committed capital and raised its full-year 2026 revenue guidance to $114–$117 million. The company also received FDA clearances for new algorithms and hardware designs, as well as Medicare New Technology Add-On Payment for delirium monitoring. CeriBell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions through its point-of-care electroencephalography platform.